DxC 500 AU Clinical Chemistry Analyzer, REF C63520 is an automated chemistry analyzer that mea...
FDA Device Recall #Z-2691-2024 — Class II — July 10, 2024
Recall Summary
| Recall Number | Z-2691-2024 |
| Classification | Class II — Moderate risk |
| Date Initiated | July 10, 2024 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Beckman Coulter Mishima K.K. |
| Location | Sunto-Gun |
| Product Type | Devices |
| Quantity | 24 analyzers |
Product Description
DxC 500 AU Clinical Chemistry Analyzer, REF C63520 is an automated chemistry analyzer that measures analytes in samples, in combination with appropriate reagents, calibrators, quality control (QC) material and other accessories. This system is for in vitro diagnostic use only.
Reason for Recall
Due to a software issues, after the instrument processes 250 racks cumulatively, any subsequent racks with samples requiring rerun/reflex will be held in the Sample Handler's Buffer area and and error code "9000" will be reported. This issue may cause a delay of results.
Distribution Pattern
Worldwide - U.S. Nationwide distribution in the states of AL, CA, GA, HI, IL, MI, MN, MS, NE, NY, OR, PA and SC. The countries of Lebanon, South Africa.
Lot / Code Information
Catalog Number: C63520 UDI-DI code: 14987666545065 Serial Numbers: 2023070010 2023060005 2023090015 2023070009 2023080011 2023080012 2023100019 2023100018 2023100020 2024010037 2024010036 2023110022 2024010038 2023090016 2024020040 2024020041 2024020039 2024020043 2024020042 2023110023 2024020045 2024020046 2024010024 2024010025
Other Recalls from Beckman Coulter Mishima K.K.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-1553-2026 | Class II | CHEMISTRY ANALYZER AU5800, REF: B96697, B96698,... | Jan 30, 2026 |
| Z-1552-2026 | Class II | DxC 700 AU, REF: B86444, B86446 | Jan 30, 2026 |
| Z-1907-2025 | Class II | Sample probe sucks a sample dispensed into a tu... | Apr 30, 2025 |
| Z-1908-2025 | Class II | Sample probe sucks a sample dispensed into a tu... | Apr 30, 2025 |
| Z-2455-2024 | Class II | DxC 500 AU Clinical Chemistry Analyzer, REF C63... | Jun 5, 2024 |
Frequently Asked Questions
A software recall means the device's embedded software or firmware has a defect that could affect its performance or safety. Many software recalls are corrected through firmware updates that can be applied without physically replacing the device. For implantable devices, the update may be delivered wirelessly during a routine clinic visit. For external devices, the manufacturer may provide updated software files or replacement units. Contact your healthcare provider to determine whether your specific device and software version are affected and what action is recommended.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.